Periorbital changes associated with topical bimatoprost

Ophthalmic Plastic and Reconstructive Surgery

Volumn 24, Issue 4, 2008, Pages 302-307

  Filippopoulos, Theodoros ^a   Paula, Jayter S ^b   Torun, Nurhan ^c   Hatton, Mark P ^d   Pasquale, Louis R ^a   Grosskreutz, Cynthia L ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; METHAZOLAMIDE; TIMOLOL MALEATE; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; DRUG DERIVATIVE; EYE DROPS;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOCHALASIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENOPHTHALMOS; EXFOLIATION SYNDROME; EYE EXAMINATION; EYELID DISEASE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN ANGLE GLAUCOMA; ORBIT DISEASE; PERIORBITAL FAT ATROPHY; PRIORITY JOURNAL; SECONDARY GLAUCOMA; SLIT LAMP; TRABECULOPLASTY; VISUAL ACUITY; ADIPOSE TISSUE; ATROPHY; CASE REPORT; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; CUTIS LAXA; DRUG EFFECT; GLAUCOMA; MIDDLE AGED; TOPICAL DRUG ADMINISTRATION;

ADIPOSE TISSUE; ADMINISTRATION, TOPICAL; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; ATROPHY; CLOPROSTENOL; CUTIS LAXA; ENOPHTHALMOS; EYELID DISEASES; FEMALE; GLAUCOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48849091287     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e31817d81df     Document Type: Article

References (31)

1. Cantor LB, WuDunn D, Cortes A, et al. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49(suppl 1):S12-S18. (Pubitemid 38317483)
2. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003;19:501-515
3. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 2001;45(suppl 4):S347-S351.
4. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703. (Pubitemid 36457976)
5. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(suppl 4):S353-S360. (Pubitemid 33043875)
6. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol 2005;123:186-192 (Pubitemid 40189705)
7. Cohen JS, Gross RL, Cheetham JK, et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004;49(suppl 1):S45-S52. (Pubitemid 38317486)
8. Centofanti M, Oddone F, Chimenti S, et al. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol 2006;142:1059-1060 (Pubitemid 44853893)
9. Casson RJ, Selva D. Lash ptosis caused by latanoprost. Am J Ophthalmol 2005;139:932-933
10. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 2004;81:574-577
11. Reader AL III. Age-related distance esotropia. J AAPOS 2007;11:69-70; author reply.
12. Rohrich RJ, Coberly DM, Fagien S, Stuzin JM. Current concepts in aesthetic upper blepharoplasty. Plast Reconstr Surg 2004;113:32e-42e.
13. Donofrio L. Technique of periorbital lipoaugmentation. Dermatol Surg 2003;29:92-98
14. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 2005;19:471-482 (Pubitemid 41819214)
15. Crowston JG, Lindsey JD, Morris CA, et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 2005;46:4571-4577
16. Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005;46:4159-4163 (Pubitemid 44264618)
17. Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology 1996;137:5641-5650 (Pubitemid 26423135)
18. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun 1997;233:200-202 (Pubitemid 27215935)
19. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 2003;305:772-785 (Pubitemid 36459199)
20. Trokel S, Kazim M, Moore S. Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology 1993;100:674-682 (Pubitemid 23143889)
21. Kazim M, Trokel SL, Acaroglu G, Elliott A. Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br J Ophthalmol 2000;84:600-605 (Pubitemid 30339310)
22. Mohadjer Y, Holds JB. Cosmetic lower eyelid blepharoplasty with fat repositioning via intra-SOOF dissection: surgical technique and initial outcomes. Ophthal Plast Reconstr Surg 2006;22:409-413 (Pubitemid 44789575)
23. Sooranna SR, Grigsby P, Myatt L, et al. Prostanoid receptors in human uterine myocytes: the effect of reproductive state and stretch. Mol Hum Reprod 2005;11:859-864
24. Romano MR, Lograno MD. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. Invest Ophthalmol Vis Sci 2007;48:3677-3682
25. Putterman AM. A clamp for strengthening Mueller's muscle in the treatment of ptosis. Modification, theory, and clamp for the Fasanella-Servat ptosis operation. Arch Ophthalmol 1972;87:665-667
26. Putterman AM, Urist M. Surgical treatment of upper eyelid retraction. Arch Ophthalmol 1972;87:401-405
27. Mercandetti M, Putterman AM, Cohen ME, et al. Internal levator advancement by Muller's muscle-conjunctival resection: technique and review. Arch Facial Plast Surg 2001;3:104-110
28. WebSite-FDA. Pharmacology Review Bimatoprost (Allergan). Available at: http://www.fda.gov/cder/foi/nda/2001/21275-Lumigan%200. 03%20percent%20Opthalmis%20Solution-pharmr-P2.pdf. Accessed August 17, 2007.
29. WebSite-FDA. Pharmacology Review Travoprost (Alcon). Available at: http://www.fda.gov/cder/foi/nda/2001/21257-Travatan-pharmr-P1.pdf. Accessed August 16, 2007.
30. WebSite-FDA. Label Latanoprost (Pharmacia). Available at: http://www.fda.gov/cder/foi/label/2001/20597s23lbl.pdf. Accessed August 18, 2007.
31. Koo L, Hatton MP, Rubin PA. When is enophthalmos "significant"? Ophthal Plast Reconstr Surg 2006;22:274-277